Drug intelligence / Profile preview

BUFY01

Development stage: Unknown
Lead developer: TRB Chemedica
Modality: Small Molecules
Administration: Ophthalmic

Overview

**BUFY01** is an investigational ophthalmic formulation developed by TRB Chemedica International SA for the treatment of **dry eye disease (DED)**. It is being evaluated in a non-inferiority clinical trial (NCT05865457, BUSTON-01) against SVS20, assessing efficacy on DED signs and symptoms, safety, and tolerability over 3 months of daily use. Participants undergo site visits, examinations, and questionnaires; the trial, not yet recruiting as of the latest data, started planning for June 2025.[1][10]

Beyond the preview

Go deeper on BUFY01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BUFY01.

Explore the full profile